Featured Content
Top 10 Journal Articles for the week of June 7th 2021
Here are the top 10 journal articles and some of the most discussed on Twitter for the week of June 7, 2021. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
Myeloma News
Unprecedented therapy found effective for blood cancer patients with no treatment options
Source: Multiple Myeloma News -- ScienceDaily Researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies. Read More
New epigenetic regulatory mechanisms involved in multiple myeloma growth
Source: Multiple Myeloma News -- ScienceDaily An international team of researchers has analyzed the function of the histone demethylase KDM5A in multiple myeloma, one of the three major hematological cancers, and clarified the mechanism by which it promotes myeloma...
Personalized cancer vaccine deemed safe, shows potential benefit against cancer
Source: Multiple Myeloma News -- ScienceDaily A personalized cancer vaccine raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an...
New CAR T-Cell therapy extends remission in heavily relapsed multiple myeloma patients
Source: Multiple Myeloma News -- ScienceDaily A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial. Read More
Glitch in genome architecture may cause B-cell malignancies
Source: Multiple Myeloma News -- ScienceDaily Restoring an enzyme that maintains the way chromosomes are packed inside cells may lead to new therapies for some blood cancers, according to a new study. Read More
Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice
Source: Multiple Myeloma News -- ScienceDaily A new study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma. Read More
Off-the-shelf immune drug shows promise in aggressive multiple myeloma
Source: Multiple Myeloma News -- ScienceDaily A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma. Read More
Treating COVID-19 in a patient with multiple myeloma
Source: Multiple Myeloma News -- ScienceDaily A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report...
New technology helps in hunt for new cancer drug combinations
Source: Multiple Myeloma News -- ScienceDaily A revolutionary new technology has been applied to reveal the inner workings of individual cancer cells - potentially identifying more effective treatment combinations for people with cancer. Read More
Lenalidomide may delay onset of myeloma-related bone, organ damage
Source: Multiple Myeloma News -- ScienceDaily The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Read More
Recent Publications
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week [...]
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and -ineligible patients with myeloma. Here, we present the largest cohort [...]
How We Approach Smoldering Multiple Myeloma.
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management [...]
Implementation of the International Myeloma Working Group reccomendations on renal impairment in multiple myeloma patients in routine clinical practice.
Click here to read the full article @ Annals of oncology : official journal of the European Society for Medical Oncology
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of [...]
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.
18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the standard technique to define minimal residual disease (MRD) status outside the bone marrow (BM) in patients with multiple myeloma [...]
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other [...]
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.
Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations. The overall goal of this study was to describe the genomic landscape of myeloma using deep whole-genome sequencing (WGS) and develop [...]
Twitter Discussions
MM_Hub: CONGRESS|#EHA2021|Katja Weisel, University Hospital Hamburg presented results from GMMG CONCEPT trial for high risk pts primary established Isa-KRd quadruplet treatment in NDMM, PFS rate of 79.6% &75.5% obtained after12 & 24 months respectively #mmsm #myeloma
CONGRESS|#EHA2021|Katja Weisel, University Hospital Hamburg presented results from GMMG CONCEPT trial for high risk pts primary established Isa-KRd quadruplet treatment in NDMM, PFS rate of 79.6% &75.5% obtained after12 & 24 months respectively #mmsm #myeloma...
MM_Hub: CONGRESS|#EHA2021| @H_Einsele, University Hospital Wurzburg discussed novel strategies like dual targeting CAR-T cells, Tri-specific T cell engaging Abs, drugs& combination with checkpoint blockers are opening new options for T cell redirecting strategies #mmsm, #myeloma
CONGRESS|#EHA2021| @H_Einsele, University Hospital Wurzburg discussed novel strategies like dual targeting CAR-T cells, Tri-specific T cell engaging Abs, drugs& combination with checkpoint blockers are opening new options for T cell redirecting strategies #mmsm,...
MM_Hub: CONGRESS|#EHA2021| @ninashah33 presented about novel immunotherapies including CAR-T, ADCs, bispecific. It was emphasized that bringing novel therapies to 1st line will bring complications. #mmsm #myeloma @UCSFMedicine
CONGRESS|#EHA2021| @ninashah33 presented about novel immunotherapies including CAR-T, ADCs, bispecific. It was emphasized that bringing novel therapies to 1st line will bring complications. #mmsm #myeloma @UCSFMedicine pic.twitter.com/d846109i7Y— Multiple Myeloma Hub...
MM_Hub: CONGRESS|#EHA2021|Maria Mateos, University of Salamanca, immune based approaches can improve disease control over time. moAB targeting CD-38 e.g. Dara & Dara-Rd has improved the outcomes. CAR-T cell incorporation in 1st line of therapy was also discussed #mmsm #myeloma
CONGRESS|#EHA2021|Maria Mateos, University of Salamanca, immune based approaches can improve disease control over time. moAB targeting CD-38 e.g. Dara & Dara-Rd has improved the outcomes. CAR-T cell incorporation in 1st line of therapy was also discussed #mmsm...
MM_Hub: CONGRESS|#EHA2021| Paola Neri, University of Calgary presented causes of immune dysfunction, strategies to reverse immune dysfunction & therapeutic complications in myeloma #mmsm, #myeloma
CONGRESS|#EHA2021| Paola Neri, University of Calgary presented causes of immune dysfunction, strategies to reverse immune dysfunction & therapeutic complications in myeloma #mmsm, #myeloma pic.twitter.com/EwQYRtoAXh— Multiple Myeloma Hub (@MM_Hub) June 14, 2021
